On December 31, 2024, Cocrystal Pharma, Inc. (COCP) announced that the Phase 2a clinical trial of its oral PB2 inhibitor CC-42344 will be continued due to an unexpectedly low influenza infection rate in study participants that were challenged with a H3N2 viral strain. The results from the study showed that CC-42344 had a favorable safety and tolerability profile, however due to the low infectivity rate the virology results were not interpretable. Cocrystal will now work with the clinical research organization to construct an amendment to the trial protocol to extend enrollment in the study and increase the likelihood of a proper infection rate for data evaluation.
